반응식
CN1CCN(C2C=CC(NC3C4[N:17]([N:29]=[CH:30]N=4)[C:18]([C:21]4[CH:22]=C(C(N)=O)SC=4)=[CH:19]N=3)=CC=2)CC1.Br[C:33]1[N:38]2[N:39]=[CH:40][N:41]=[C:37]2[C:36]([NH:42][C:43]2[CH:48]=[CH:47][C:46]([N:49]3[CH2:54][CH2:53][O:52][CH2:51][CH2:50]3)=[CH:45][CH:44]=2)=[N:35][CH:34]=1.C(C1N(C2CCCCO2)N=CC=1B1OC(C)(C)C(C)(C)O1)C.C(C1C(B2OC(C)(C)C(C)(C)O2)=CN(C2CCCCO2)N=1)C.C([O-])([O-])=O.[Na+].[Na+]>O1CCOCC1.C1C=CC([P]([Pd]([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)[P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1>[CH2:21]([C:18]1[NH:17][N:29]=[CH:30][C:19]=1[C:33]1[N:38]2[N:39]=[CH:40][N:41]=[C:37]2[C:36]([NH:42][C:43]2[CH:48]=[CH:47][C:46]([N:49]3[CH2:54][CH2:53][O:52][CH2:51][CH2:50]3)=[CH:45][CH:44]=2)=[N:35][CH:34]=1)[CH3:22]참가 물질
8
반응물 5
생성물 1
시약·촉매·용매 2
실험 절차
This compound may be prepared using methods as described for Compound 6, step 4 using (5-bromo-[1,2,4]triazolo[1,5-a]pyrazin-8-yl)-(4-morpholin-4-yl-phenyl)-amine (0.032 g, 0.085 mmol), 5-ethyl-1-(tetrahydro-pyran-2-yl)-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole and 3-ethyl-1-(tetrahydro-pyran-2-yl)-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole (0.52 mg, 0.17 mmol), and Pd(PPh3)4 (0.025 mg, 0.021 mmol) in 1.5M Na2CO3 (aq) (0.45 mL, 0.6 mmol) and dioxane (2 mL). The reaction mixture is purified by silica gel column chromatography eluting with 1:1 petroleum ether:ethyl acetate followed by 1:4 petroleum ether:ethyl acetate to yield the title compound (45 mg).
후처리
- customThis compound may be prepared
- customThe reaction mixture is purified by silica gel column chromatography
- washeluting with 1:1 petroleum ether
출처 및 근거
- ORD 기록
- ord-ba2c2a6c05c14a228a92032af735bc6e
- 출처 데이터셋
- uspto-grants-2011_03
- 특허 번호
- US07915256B2
연결된 노트
불러오는 중…